A Phase 1 interventional study of Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) in Ventricular Tachycardia, sponsored by University of Zurich. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by University of Zurich · Phase 1, Interventional, and Treatment
Among 21 studies in Tachycardia, Ventricular with a site in Switzerland — 6 open to participants now, 7 under way, none of them phase 3. Tachycardia, Ventricular · Switzerland.
Among the 21 studies in Tachycardia, Ventricular with a site in Switzerland, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 1, and was the 17th registered.
451 studies on the registry are indexed under Tachycardia, Ventricular; 120 are open to participants now.
Browse Tachycardia, Ventricular studies →6 of the 21 studies in Tachycardia, Ventricular with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
University Hospital, Basel, Switzerland · Sites in Switzerland, United States, Austria and 13 more countries
University Hospital, Basel, Switzerland · Sites in Switzerland
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Switzerland, Italy
Western Sydney Local Health District · Sites in Switzerland, United States, Australia and 12 more countries
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 85 Tachycardia, Ventricular studies recruiting now, 66 (78%) set no upper age limit and 1 (1%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 15 is below the median of 71 across 280 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 151 across the 14 interventional studies, 870 across the 7 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 21 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,049 studies on the registry; 133 are open to participants now.
University of Zurich has 1 study filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
1 of the studies in Tachycardia, Ventricular with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07201506Insel Gruppe AG, University Hospital BernReal-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation | 2027-03-25 |
Among the 21 studies in Tachycardia, Ventricular with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a significantly reduced long-term VT recurrence rate compared to the currently applied single dose of 25 Gy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with structural heart disease, in particular ischemic and non-ischemic cardiomyopathy: Implanted ICD and/or CRT-D. Prior ≥1 failed catheter ablation (with endocardial ± epicardial approach based on the substrate location and the morphology of clinical VTs) procedure to control sustained monomorphic VT using currently recommended mapping and ablation techniques,2 or patients in whom ablation is not feasible. Reasons for lack of epicardial ablation and non-feasibility of catheter ablation must be specified. Sustained VT recurrence after catheter ablation on optimised antiarrhythmic medication.
Age ≥18 years. IRB-approved, written must be provided
Exclusion Criteria:
Patients with only premature ventricular contractions.
Patients with sustained VT/VF who demonstrate:
Acute myocardial infarction; Primary electrical disease (channelopathy); Reversible and treatable cause (e.g., drug-induced or intoxication) of VT that can be adequately addressed otherwise; A target that cannot be safely and precisely defined based on stereotactic radiotherapy accuracy requirements (e.g., anatomical interference from OARs, overlapping prior radiation therapy to the thoracic region); Pregnancy or breastfeeding; Inability to provide .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)
Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
safety measured by registered radiation associated adverse events up to 90 days
safety measured by registered radiation associated adverse events
Time frame: up to 90 days
Radiation associated serious adverse event (at least grade 4 or 5 according to CTCAE v5)
Time frame: As assessed at 90 days
Plan to share: Undecided
Started Jul 2022 (actual). Primary completion is estimated for Dec 2027, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.